Investigation on a Topical Cosmetic Pain Lotion (Egyfil) for Stiffness and Pain Relief

Not Applicable

Completed

• Conditions: Muscle Rigidity; Pain
• Interventions: Other: Egyfil Pain Lotion

• Registration Number: NCT05711953
• Lead Sponsor: Contrad Swiss SA

Brief Summary

The application of a novel topical formulation for the treatment of muscular pain and stiffness (Egyfil), containing hyaluronic acid, SH-Polypeptide-6 and SH-Oligopeptide-1, is investigated to evaluate efficacy and safety in 26 patients with stiffness and pain. Single-Arm, Pre-Market, interventional study.

Detailed Description

26 male and female patients, ranging from 24 to 78 years old, will receive Egyfil Pain Lotion given for the treatment of pain and stiffness over a three-days period. The primary objective of the study is to evaluate the clinical performance of the lotion in providing relief from stiffness, reduced mobility, and muscle tension pain.

Study Timeline

• Study Start: 2021-06-12
• Primary Completion: 2021-07-20
• Study Completion: 2021-07-20
• Study First Submitted: 2023-01-25
• Study First Submitted QC: 2023-01-25
• Study First Posted: 2023-02-03
• Status Verified: 2023-07
• Last Update Submitted: 2023-07-19
• Last Update Posted: 2023-07-20

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 26

Inclusion Criteria

1. signed participants informed consent form (ICF);
2. male or Female, aged > 18 years at the time of the signature of ICF;
3. 3 to 10 rating according to the Numerical Rating Scale (NRS), applied in participants with muscle tension pain;
4. willing to follow all study procedures;
5. willing to follow indications.

Exclusion Criteria

1. use of analgesics within the 24 hours prior to V1;
2. damaged skin in the area of treatment;
3. infective or prior inflammatory processes near the area of treatment;
4. ongoing cutaneous allergies;
5. serious and chronical pathological skin conditions (i.e., rosacea, psoriasis, vitiligo) including diagnosticated cancer with/without ongoing antitumor therapy;
6. allergy to lotion components (aqua (water), glycerin, caprylic/capric triglyceride, aloe barbadensis leaf juice powder, simmondsia chinensis seed oil (simmondsia chinensis (jojoba) seed oil), phenoxyethanol, ammonium acryloyldimethyltaurate/vp copolymer, carbomer, tocopheryl acetate, tocopherol, benzoic acid, sodium hydroxide, sodium hyaluronate, dehydroacetic acid, ethylhexylglycerin, butyrospermum parkii butter (butyrospermum parkii (shea butter)), sorbitol, SH-polypeptide 6; SH-oligopeptide-1
7. immune system illnesses;
8. uncontrolled systemic diseases;
9. known drug and/or alcohol abuse;
10. mental incapacity that precludes adequate understanding or cooperation;
11. participation in another investigational study.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Egyfil Pain Lotion	Egyfil Pain Lotion	Interventional study on Egyil 50mL will be topically administered ad libitum for three days.

Primary Outcome Measures

Name	Time	Method
Muscle Stiffness, measured by Numerical Rating Scale (NRS)	3 days	The primary efficacy endpoint of the study will be the evaluation of the clinical performance of the Egyfil, used as intended in patients affected by muscle stiffness, in terms of difference in NRS score between the end study visit and baseline visit, assessed by patients; Minimum index score: 0. Maximum index score: 10; 0 means no stiffness
Pain, measured by Numerical Rating Scale (NRS)	3 days	The primary efficacy endpoint of the study will be the evaluation of the clinical performance of the Egyfil, used as intended in patients affected by Pain, in terms of difference in NRS score between the end study visit and baseline visit, assessed by patients; Minimum index score: 0. Maximum index score: 10; 0 means no pain

Secondary Outcome Measures

Name	Time	Method
To evaluate the safety and tolerability of Pain Lotion when topically applied.	3 days	To evaluate eventual side effects of the product Egyfil through the assessment made by the Principal Investigator.; Number of Participants with adverse events.

Trial Locations

Locations (1)

Stefano Picotti; 🇮🇹 Cardano Al Campo, Varese, Italy